CN108210873B

CN108210873B - Traditional Chinese medicine composition for increasing estrogen and application thereof

Info

Publication number: CN108210873B
Application number: CN201810305067.4A
Authority: CN
Inventors: 高鹏飞; 潘丹青; 张岚; 徐月妹; 肖茜
Original assignee: Jinshan Hospital of Fudan University
Current assignee: Jinshan Hospital of Fudan University
Priority date: 2018-04-08
Filing date: 2018-04-08
Publication date: 2020-11-03
Anticipated expiration: 2038-04-08
Also published as: CN108210873A

Abstract

The invention relates to a traditional Chinese medicine composition for increasing estrogen, which is prepared from the following raw material medicines: white peony root fried with honey bran, white poria, cassia twig, radix bupleuri, mint, rhizoma atractylodis fried with honey bran, ligusticum wallichii, peach kernel, liquorice fried with honey, rhizoma alismatis, angelica, tree peony bark and dried ginger. The invention also provides application of the traditional Chinese medicine composition. Its advantages are: the traditional Chinese medicine composition provided by the invention is proper in compatibility, and can play a role in increasing estrogen under the comprehensive action of various raw material medicines. The traditional Chinese medicine composition can be used for treating estrogen-related diseases, such as climacteric syndrome, postmenopausal osteoporosis and the like.

Description

Traditional Chinese medicine composition for increasing estrogen and application thereof

Technical Field

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for increasing estrogen and application thereof.

Background

Female menopause refers to a period of time before and after menopause, and is a special physiological stage for transition from the reproductive phase to the old age phase, including before and after perimenopause. The climacteric women have symptoms of different degrees, such as menstrual change, flushing, palpitation, insomnia, hypodynamia, depression, anxiety, emotional instability, easy excitation and difficulty in concentration due to hypoovarianism, hyperpituitarism and excessive gonadotropin secretion to cause vegetative nerve dysfunction, and are called climacteric syndrome. According to the statistics of related data at home and abroad, 90% of women aged 45-50 have different degrees of clinical manifestations, and therefore, related diseases are caused. With the trend of aging and development of human beings, the prevention and treatment of climacteric syndrome become a medical subject and a social problem which are concerned globally.

The traditional Chinese medicine considers that the climacteric onset of women is caused by factors such as age increase, labor, birth, weakness and sickliness, and the like, so that kidney qi is weakened, thoroughfare vessel is deficient, sex is exhausted, viscera function is disordered, and yin-yang balance is disordered. Kidney deficiency is the main pathogenesis, kidney is the congenital origin, and kidney failure inevitably affects heart, liver and spleen to cause dysfunction, and causes various pathological changes.

According to western medicine, the imbalance of neurotransmitter, hormone, cytokine and the like caused by the dysfunction of hypothalamus-pituitary-ovary axis or adrenal gland due to the excessive reduction of estrogen level is considered as the main cause of climacteric onset. Therefore, neuroendocrine immunity is most closely related to climacteric syndrome. Clinical and experimental studies have shown that: the blood FSH and LH level of the climacteric syndrome group is higher than that of the normal climacteric group, and the E2 level is obviously reduced compared with that of the normal climacteric group, which indicates that the excessive reduction of estrogen is the basis of the climacteric syndrome.

Chinese patent ZL200510079323.5 discloses a Chinese medicinal composition for treating female climacteric syndrome: 3-12 g of tortoise plastron, 2-12 g of herba epimedii, 0.1-3 g of sea horse, 3-15 g of medlar, 3-15 g of fleece-flower root, 2-9 g of rhizoma anemarrhenae, 2-9 g of rhizoma polygonati, 2-9 g of radix scutellariae, 1-6 g of coptis chinensis, 2-9 g of gypsum, 2-9 g of rheum officinale, 3-9 g of spina date seed and 2-9 g of peach kernel. Chinese patent literature ZL200810055116.X discloses a medicament for treating climacteric syndrome: semen Cuscutae, fructus Lycii, fructus Schisandrae chinensis, fructus Cnidii, fructus Rosae Laevigatae, Rubi fructus, semen Allii Tuberosi, radix Morindae officinalis, Cistanchis herba, rehmanniae radix, radix Cyathulae, herba Epimedii, Ginseng radix, cornu Cervi Pantotrichum, Hippocampus, and fructus Toosendan. Chinese patent ZL200610126232.7 discloses a Chinese medicament for preventing and treating climacteric syndrome: 1-50 parts of angelica, 1-100 parts of astragalus and 0.1-100 parts of epimedium. However, no report is found about the traditional Chinese medicine composition for increasing estrogen.

Disclosure of Invention

The first purpose of the present invention is to provide a Chinese medicine composition for increasing estrogen in order to overcome the defects in the prior art.

The second purpose of the invention is to provide an application of the traditional Chinese medicine composition.

In order to achieve the first purpose, the invention adopts the technical scheme that: a traditional Chinese medicine composition for increasing estrogen is prepared from the following raw material medicines in parts by weight: 8-16 parts of honey bran-fried white paeony root, 8-16 parts of white poria, 10-20 parts of cassia twig, 4-8 parts of radix bupleuri, 2-4 parts of mint, 6-12 parts of honey bran-fried rhizoma atractylodis, 4-8 parts of ligusticum wallichii, 4-8 parts of semen persicae, 2-4 parts of honey-fried liquorice, 6-12 parts of rhizoma alismatis, 10-20 parts of angelica sinensis, 6-12 parts of moutan bark and 4-8 parts of dried ginger.

Preferably, the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 10-14 parts of honey bran-fried white paeony root, 10-14 parts of white poria, 12.5-17.5 parts of cassia twig, 5-7 parts of radix bupleuri, 2.5-3.5 parts of mint, 7.5-10.5 parts of honey bran-fried rhizoma atractylodis, 5-7 parts of ligusticum wallichii, 5-7 parts of peach kernel, 2.5-3.5 parts of honey-fried liquorice, 7.5-10.5 parts of rhizoma alismatis, 12.5-17.5 parts of angelica sinensis, 7.5-10.5 parts of moutan bark and 5-7 parts of dried ginger.

Preferably, the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 12 parts of honey bran-fried white paeony root, 12 parts of white poria, 15 parts of cassia twig, 6 parts of radix bupleuri, 3 parts of mint, 9 parts of honey bran-fried rhizoma atractylodis, 6 parts of ligusticum wallichii, 6 parts of semen persicae, 3 parts of honey-fried liquorice, 9 parts of rhizoma alismatis, 15 parts of angelica, 9 parts of cortex moutan radicis and 6 parts of rhizoma zingiberis.

In order to achieve the second object, the invention adopts the technical scheme that: the application of the traditional Chinese medicine composition in preparing a medicine for increasing estrogen is provided.

The application of the traditional Chinese medicine composition in preparing a medicine for treating climacteric syndrome.

The traditional Chinese medicine composition is applied to preparation of a medicine for treating postmenopausal osteoporosis.

The medicament dosage form is an oral preparation.

The invention has the advantages that:

1. the traditional Chinese medicine composition provided by the invention is proper in compatibility, and can play a role in increasing estrogen under the comprehensive action of various raw material medicines.

2. The traditional Chinese medicine composition can be used for treating climacteric syndrome, and has obvious curative effect through clinical verification.

3. The traditional Chinese medicine composition can also be used for treating other estrogen related diseases, such as postmenopausal osteoporosis.

Detailed Description

The following examples are provided to illustrate specific embodiments of the present invention.

Example 1

12 parts of honey bran-fried white paeony root, 12 parts of white poria, 15 parts of cassia twig, 6 parts of radix bupleuri, 3 parts of mint, 9 parts of honey bran-fried rhizoma atractylodis, 6 parts of ligusticum wallichii, 6 parts of semen persicae, 3 parts of honey-fried liquorice, 9 parts of rhizoma alismatis, 15 parts of angelica, 9 parts of cortex moutan radicis and 6 parts of rhizoma zingiberis.

Example 2

10 parts of honey bran-fried white paeony root, 10 parts of white poria, 12.5 parts of cassia twig, 5 parts of radix bupleuri, 2.5 parts of mint, 7.5 parts of honey bran-fried rhizoma atractylodis, 5 parts of ligusticum wallichii, 5 parts of peach kernel, 5 parts of honey-fried liquorice, 7.5 parts of rhizoma alismatis, 12.5 parts of angelica, 7.5 parts of moutan bark and 5 parts of dried ginger.

Example 3

10 parts of honey bran-fried white paeony root, 12 parts of white poria, 15 parts of cassia twig, 6 parts of radix bupleuri, 2.5 parts of mint, 9 parts of honey bran-fried rhizoma atractylodis, 6 parts of ligusticum wallichii, 6 parts of smooth peach kernel, 5 parts of honey-fried liquorice, 9 parts of rhizoma alismatis, 15 parts of angelica, 9 parts of moutan bark and 5 parts of dried ginger.

Example 4

10 parts of honey bran-fried white paeony root, 14 parts of white poria, 17.5 parts of cassia twig, 7 parts of radix bupleuri, 2.5 parts of mint, 10.5 parts of honey bran-fried rhizoma atractylodis, 7 parts of ligusticum wallichii, 7 parts of semen persicae, 5 parts of honey-fried liquorice, 10.5 parts of rhizoma alismatis, 17.5 parts of angelica, 10.5 parts of moutan bark and 5 parts of dried ginger.

Example 5

12 parts of white paeony root fried with honey bran, 10 parts of white poria, 15 parts of cassia twig, 7 parts of radix bupleuri, 3 parts of mint, 7.5 parts of rhizoma atractylodis fried with honey bran, 6 parts of ligusticum wallichii, 7 parts of peach kernel, 6 parts of liquorice processed with honey, 7.5 parts of rhizoma alismatis, 15 parts of angelica, 10.5 parts of moutan bark and 6 parts of dried ginger.

Example 6

12 parts of white paeony root fried with honey bran, 12 parts of white poria, 17.5 parts of cassia twig, 5 parts of radix bupleuri, 3 parts of mint, 9 parts of rhizoma atractylodis fried with honey bran, 7 parts of ligusticum wallichii, 5 parts of peach kernel, 6 parts of liquorice processed with honey, 9 parts of rhizoma alismatis, 17.5 parts of angelica, 7.5 parts of moutan bark and 6 parts of dried ginger.

Example 7

12 parts of white paeony root fried with honey bran, 14 parts of white poria, 12.5 parts of cassia twig, 6 parts of radix bupleuri, 3 parts of mint, 10.5 parts of rhizoma atractylodis fried with honey bran, 5 parts of ligusticum wallichii, 6 parts of peach kernel, 6 parts of liquorice processed with honey, 10.5 parts of rhizoma alismatis, 12.5 parts of angelica, 9 parts of moutan bark and 6 parts of dried ginger.

Example 8

14 parts of white paeony root fried with honey bran, 10 parts of white poria, 17.5 parts of cassia twig, 6 parts of radix bupleuri, 3.5 parts of mint, 7.5 parts of rhizoma atractylodis fried with honey bran, 7 parts of ligusticum wallichii, 6 parts of semen persicae, 7 parts of liquorice processed with honey, 7.5 parts of rhizoma alismatis, 17.5 parts of angelica, 9 parts of moutan bark and 7 parts of dried ginger.

Example 9

14 parts of white paeony root fried with honey bran, 12 parts of white poria, 12.5 parts of cassia twig, 7 parts of radix bupleuri, 3.5 parts of mint, 9 parts of rhizoma atractylodis fried with honey bran, 5 parts of ligusticum wallichii, 7 parts of peach kernel, 7 parts of liquorice roasted with honey, 9 parts of rhizoma alismatis, 12.5 parts of angelica, 10.5 parts of moutan bark and 7 parts of dried ginger.

Example 10

14 parts of white paeony root fried with honey bran, 14 parts of white poria, 15 parts of cassia twig, 5 parts of radix bupleuri, 3.5 parts of mint, 10.5 parts of rhizoma atractylodis fried with honey bran, 6 parts of ligusticum wallichii, 5 parts of peach kernel, 7 parts of liquorice processed with honey, 10.5 parts of rhizoma alismatis, 15 parts of angelica, 7.5 parts of moutan bark and 7 parts of dried ginger.

Example 11

8 parts of honey bran-fried white paeony root, 8 parts of white poria, 10 parts of cassia twig, 4 parts of radix bupleuri, 2 parts of mint, 6 parts of honey bran-fried rhizoma atractylodis, 4 parts of ligusticum wallichii, 4 parts of semen persicae, 4 parts of honey-fried liquorice, 6 parts of rhizoma alismatis, 10 parts of angelica, 6 parts of cortex moutan radicis and 4 parts of rhizoma zingiberis.

Example 12

8 parts of honey bran-fried white paeony root, 12 parts of white poria, 15 parts of cassia twig, 6 parts of radix bupleuri, 2 parts of mint, 9 parts of honey bran-fried rhizoma atractylodis, 6 parts of ligusticum wallichii, 6 parts of semen persicae, 4 parts of honey-fried liquorice, 9 parts of rhizoma alismatis, 15 parts of angelica, 9 parts of cortex moutan radicis and 4 parts of rhizoma zingiberis.

Example 13

8 parts of honey bran-fried white paeony root, 16 parts of white poria, 20 parts of cassia twig, 8 parts of radix bupleuri, 2 parts of mint, 12 parts of honey bran-fried rhizoma atractylodis, 8 parts of ligusticum wallichii, 8 parts of peach kernel, 4 parts of honey-fried liquorice, 12 parts of rhizoma alismatis, 20 parts of angelica, 12 parts of moutan bark and 4 parts of dried ginger.

Example 14

12 parts of honey bran-fried white paeony root, 8 parts of white poria, 15 parts of cassia twig, 8 parts of radix bupleuri, 3 parts of mint, 6 parts of honey bran-fried rhizoma atractylodis, 6 parts of ligusticum wallichii, 8 parts of semen persicae, 6 parts of honey-fried liquorice, 6 parts of rhizoma alismatis, 15 parts of angelica, 12 parts of moutan bark and 6 parts of rhizoma zingiberis.

Example 15

12 parts of honey bran-fried white paeony root, 12 parts of white poria, 20 parts of cassia twig, 4 parts of radix bupleuri, 3 parts of mint, 9 parts of honey bran-fried rhizoma atractylodis, 8 parts of ligusticum wallichii, 4 parts of peach kernel, 6 parts of honey-fried liquorice, 9 parts of rhizoma alismatis, 20 parts of angelica, 6 parts of moutan bark and 6 parts of dried ginger.

Example 16

12 parts of honey bran-fried white paeony root, 16 parts of white poria, 10 parts of cassia twig, 6 parts of radix bupleuri, 3 parts of mint, 12 parts of honey bran-fried rhizoma atractylodis, 4 parts of ligusticum wallichii, 6 parts of semen persicae, 6 parts of honey-fried liquorice, 12 parts of rhizoma alismatis, 10 parts of angelica, 9 parts of moutan bark and 6 parts of rhizoma zingiberis.

Example 17

16 parts of honey bran-fried white paeony root, 8 parts of white poria, 20 parts of cassia twig, 6 parts of radix bupleuri, 4 parts of mint, 6 parts of honey bran-fried rhizoma atractylodis, 8 parts of ligusticum wallichii, 6 parts of peach kernel, 8 parts of honey-fried liquorice, 6 parts of rhizoma alismatis, 20 parts of angelica, 9 parts of moutan bark and 8 parts of dried ginger.

Example 18

16 parts of honey bran-fried white paeony root, 12 parts of white poria, 10 parts of cassia twig, 8 parts of radix bupleuri, 4 parts of mint, 9 parts of honey bran-fried rhizoma atractylodis, 4 parts of ligusticum wallichii, 8 parts of peach kernel, 8 parts of honey-fried liquorice, 9 parts of rhizoma alismatis, 10 parts of angelica, 12 parts of moutan bark and 8 parts of dried ginger.

Example 19

16 parts of honey bran-fried white paeony root, 16 parts of white poria, 15 parts of cassia twig, 4 parts of radix bupleuri, 4 parts of mint, 12 parts of honey bran-fried rhizoma atractylodis, 6 parts of ligusticum wallichii, 4 parts of peach kernel, 8 parts of honey-fried liquorice, 12 parts of rhizoma alismatis, 15 parts of angelica, 6 parts of moutan bark and 8 parts of dried ginger.

Comparative example 1

6 parts of angelica, 6 parts of white peony root, 6 parts of bighead atractylodes rhizome, 6 parts of poria cocos, 6 parts of radix bupleuri, 4 parts of liquorice, 4 parts of cape jasmine, 4 parts of moutan bark, 2 parts of mint and 1 part of ginger.

Comparative example 2

8 parts of cassia twig, 8 parts of tuckahoe, 8 parts of tree peony bark, 8 parts of peach kernel and 8 parts of white paeony root.

Comparative example 3

8 parts of Chinese herbaceous peony, 8 parts of tuckahoe, 8 parts of atractylodes macrocephala, 8 parts of alisma orientale, 6 parts of angelica and 6 parts of hemlock parsley.

Example 20

Data and method

1 case selection

All cases are climacteric syndrome patients who are in clinic; selecting for complaints about menstrual disorders or menopauseThen, hot sweating, hectic fever and flushing, soreness and weakness of waist and knees, feverish palms and soles, restlessness, insomnia and dreamful sleep, dry mouth, reddened tongue with little coating, and thready and rapid pulse appear; the selected individuals have the symptoms of 6 or more, elevated levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH), and estradiol (E)₂) A decrease in level; patients with cardiovascular and mental diseases are excluded.

2 general data

97 patients are divided into two groups according to the treatment sequence, wherein 49 patients in the treatment group are aged 41-55 years, and the average course of disease is 6 months-5 years; 48 control groups are aged 42-55 years and the disease course is 5 months-5 years. The data of two groups of patients have no statistical difference (P is more than 0.05) and are comparable.

3 methods of treatment

Treatment groups: example 1A Chinese medicinal composition is administered 1 dose daily for 1 month.

Control group: vitamin E is orally administered at a dose of 100mg each time, 2 times daily; oryzanol is orally administered 20mg each time, 3 times daily. The administration is continued for 1 month.

4 items of observation

In all cases, the changes of hot sweating, flush, soreness and weakness of waist and knees, dry mouth, restlessness, insomnia, dreaminess, feverish palms and soles, tongue condition, pulse condition and other symptoms are recorded in the table before the treatment starts, 2 weeks after the treatment and after the treatment ends. The symptoms are determined by a semi-quantitative method: the scores of 0, 1, 2 and 3 are respectively recorded according to the symptom of no symptom, mild symptom, moderate symptom and severe symptom.

Serum FSH, LH and E were measured before and after treatment₂And (4) content.

5 standard of therapeutic effect

And (4) judging according to the traditional Chinese medicine syndrome integral.

The effect is shown: the clinical symptoms disappear, or the symptoms are obviously improved, and the total integral value is reduced by more than or equal to 70 percent.

The method has the following advantages: symptoms improved, and the total integral value decreased by more than or equal to 30% but less than 70%.

And (4) invalidation: symptoms and signs are not improved, and the total integral value is reduced by not more than 30 percent.

Second, result in

The results of the therapeutic effect of 1 group of patients are shown in Table 1. The curative effect result of the treatment group is obviously better than that of the control group, and the difference is significant (P is less than 0.05).

TABLE 1 comparison of the results of the treatment of two groups of patients

The results of the comparison of the symptom scores before and after treatment in the two groups of patients are shown in Table 2. After treatment, the symptom of the treatment group is improved obviously better than that of the control group, and the difference is significant (P is less than 0.05).

TABLE 2 comparison of symptom scores for two groups of patients

Example 21

1 clinical data

25 patients with postmenopausal osteoporosis who are outpatient in our hospital, with the average age of 58.9 ± 3.9 years.

2 method of treatment

The Chinese medicinal composition of example 1 was administered 1 dose daily for 3 months.

3 index detection

The bone density of 1-4 lumbar vertebrae was measured before and after treatment.

4 results

After treatment, the bone density of the traditional Chinese medicine composition disclosed by the embodiment 1 of the invention is obviously improved compared with that before treatment.

The bone density before treatment is 0.676 +/-0.129 g/cm²The bone density after treatment is 0.749 +/-0.159 g/cm²。

Example 22

1. Animal model: SD healthy female infertile rats of 3-4 months of age, 60, clean grade; the animal model conforming to the climacteric expression is prepared by a conventional method.

2. Grouping experiments: 100 rats, randomly divided into 10 groups of 10 rats each, respectively:

group A: in normal group, the distilled water is filled in 14 ml/kg. d

Group B: the model control group is drenched with 14 ml/kg. d of distilled water

Group C: the Chinese medicinal composition of example 1, administered in an amount of 0.97g/kg d

Group D: the Chinese medicinal composition of example 1, administered in an amount of 0.49g/kg d

Group E: the Chinese medicinal composition of example 9, administered in an amount of 0.97g/kg d

And F group: the Chinese medicinal composition of example 16, administered in an amount of 0.97g/kg d

Group G: climacteric syndrome relieving tablet, administration dosage is 0.97g/kg d

Group H: the Chinese medicinal composition of comparative example 1, administered in an amount of 0.97 g/kg. d

Group I: comparative example 2 Chinese medicinal composition, administration dose 0.97 g/kg. d

Group J: the Chinese medicinal composition of comparative example 3, administered in an amount of 0.97 g/kg. d

The rats of each group are continuously gavaged for 30 days, and the administration dosage is 0.97g/kg d

3. Detection indexes are as follows: serum E₂FSH, LH levels, uterine index

1 hour after the last administration, the rats were anesthetized, the abdominal aorta was bled, and serum was isolated (serum E was assayed by radioimmunoassay₂FSH, LH levels); taking out uterus, performing conventional treatment, weighing out wet weight, and calculating organ coefficient according to the following formula

Uterus index ═ wet weight of uterus (mg)/weight of rat (g)

4. Results

The results of the indexes of the rats in each group are shown in tables 3 to 6.

TABLE 3 Experimental drugs vs. castrated rat serum E₂Influence of level

TABLE 4 Effect of the test drugs on serum FSH levels in castrated rats

TABLE 5 Effect of the test drugs on serum LH levels in castrated rats

TABLE 6 Effect of the test drugs on uterine index of castrated rats

Example 23

Weighing the medicinal materials according to the proportion of the traditional Chinese medicine composition in the embodiment 1-19, adding 12 times of water, soaking for 1 hour, extracting, decocting for 1 hour for the first time, adding 8 times of water for the second time, decocting for 1 hour, combining the decoctions, filtering, concentrating the filtrate under reduced pressure, adding ethanol under stirring until the ethanol content reaches 60%, standing for 48 hours, filtering, concentrating the filtrate until no ethanol smell exists, recovering the ethanol, and keeping the concentrated solution for later use. Concentrating the concentrated solution to obtain clear paste with the relative density of 1.12-1.21, adding a proper amount of preservative, adding pure water to dissolve, uniformly mixing, filling and sterilizing to obtain the oral liquid.

Example 24

Weighing the medicinal materials according to the proportion of the traditional Chinese medicine composition in the embodiment 1-19, adding 12 times of water, soaking for 1 hour, extracting, decocting for 1 hour for the first time, adding 8 times of water for the second time, decocting for 1 hour, combining the decoctions, filtering, concentrating the filtrate under reduced pressure, adding ethanol under stirring until the ethanol content reaches 60%, standing for 48 hours, filtering, concentrating the filtrate until no ethanol smell exists, and recovering the ethanol. Concentrating the concentrated solution to obtain extract, spray drying to obtain extract powder, drying, grading, and packaging to obtain granule.

Example 25

Weighing the medicinal materials according to the proportion of the traditional Chinese medicine composition in the embodiment 1-19, adding 12 times of water, soaking for 1 hour, extracting, decocting for 1 hour for the first time, adding 8 times of water for the second time, decocting for 1 hour, combining the decoctions, filtering, concentrating the filtrate under reduced pressure, adding ethanol under stirring until the ethanol content reaches 60%, standing for 48 hours, filtering, concentrating the filtrate until no ethanol smell exists, and recovering the ethanol. Concentrating the concentrated solution to obtain extract, spray drying the extract, granulating, drying, grading, and tabletting to obtain tablet.

Example 26

Weighing the medicinal materials according to the proportion of the traditional Chinese medicine composition in the embodiment 1-19, adding 12 times of water, soaking for 1 hour, extracting, decocting for 1 hour for the first time, adding 8 times of water for the second time, decocting for 1 hour, combining the decoctions, filtering, concentrating the filtrate under reduced pressure, adding ethanol under stirring until the ethanol content reaches 60%, standing for 48 hours, filtering, concentrating the filtrate until no ethanol smell exists, and recovering the ethanol. Concentrating the concentrated solution to obtain extract, spray drying the extract, granulating, drying, grading, and encapsulating to obtain capsule.

The above description is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, several modifications and additions can be made without departing from the method of the present invention, and these modifications and additions should also be regarded as the protection scope of the present invention.

Claims

1. The traditional Chinese medicine composition for increasing estrogen is characterized by being prepared from the following raw material medicines in parts by weight: 8-16 parts of honey bran-fried white paeony root, 8-16 parts of white poria, 10-20 parts of cassia twig, 4-8 parts of radix bupleuri, 2-4 parts of mint, 6-12 parts of honey bran-fried rhizoma atractylodis, 4-8 parts of ligusticum wallichii, 4-8 parts of semen persicae, 2-4 parts of honey-fried liquorice, 6-12 parts of rhizoma alismatis, 10-20 parts of angelica sinensis, 6-12 parts of moutan bark and 4-8 parts of dried ginger.

2. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight: 10-14 parts of honey bran-fried white paeony root, 10-14 parts of white poria, 12.5-17.5 parts of cassia twig, 5-7 parts of radix bupleuri, 2.5-3.5 parts of mint, 7.5-10.5 parts of honey bran-fried rhizoma atractylodis, 5-7 parts of ligusticum wallichii, 5-7 parts of peach kernel, 2.5-3.5 parts of honey-fried liquorice, 7.5-10.5 parts of rhizoma alismatis, 12.5-17.5 parts of angelica sinensis, 7.5-10.5 parts of moutan bark and 5-7 parts of dried ginger.

3. The traditional Chinese medicine composition according to claim 1, which is prepared from the following raw materials in parts by weight: 12 parts of honey bran-fried white paeony root, 12 parts of white poria, 15 parts of cassia twig, 6 parts of radix bupleuri, 3 parts of mint, 9 parts of honey bran-fried rhizoma atractylodis, 6 parts of ligusticum wallichii, 6 parts of semen persicae, 3 parts of honey-fried liquorice, 9 parts of rhizoma alismatis, 15 parts of angelica, 9 parts of cortex moutan radicis and 6 parts of rhizoma zingiberis.

4. Use of a Chinese medicinal composition according to any one of claims 1 to 3 in the preparation of a medicament for increasing estrogen.

5. Use of the Chinese medicinal composition according to any one of claims 1 to 3 in the preparation of a medicament for treating climacteric syndrome.

6. Use of a Chinese medicinal composition according to any one of claims 1 to 3 in the preparation of a medicament for the treatment of postmenopausal osteoporosis.

7. The use according to any one of claims 4 to 6, wherein the pharmaceutical dosage form is an oral formulation.